Omega Liquidating, Inc., formerly Omega Therapeutics, Inc., was a clinical-stage biotechnology company, which was engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code. The Company remains in possession of its assets and continues to operate its business as a debtor in possession.

Employees

Sector

Investment Holding Companies

More about the company

Market Closed - OTC Markets 15:31:48 08/08/2025 BST			5-day change	1st Jan Change
0.003000 ^USD	+50.00%		-.--%	-

08/08/25	Omega Therapeutics, Inc. Went Out of Business	CI
31/07/25	Revised Combined Liquidation Plan and Disclosure Statement Approved for Omega Therapeutics, Inc.	CI

Market Cap	41.28M 36.31M 34.33M 31.14M 58.48M 3.96B 58.82M 411M 159M 2.02B 155M 152M 6.5B	P/E 2022	-2.66x	P/E 2023	-1.67x
Enterprise Value	96.28M 84.68M 80.07M 72.63M 136M 9.24B 137M 959M 370M 4.72B 361M 354M 15.15B	EV / Sales 2022	83,097,425x	EV / Sales 2023	71,420,793x
Free-Float	98.38%	Yield 2022 *	-	Yield 2023	-

08/08/25	Omega Therapeutics, Inc. Went Out of Business	CI
31/07/25	Revised Combined Liquidation Plan and Disclosure Statement Approved for Omega Therapeutics, Inc.	CI
07/07/25	First Motion for Exclusivity Period Extension Approved For Omega Therapeutics, Inc.	CI
13/06/25	Modified Disclosure Statement and Liquidation Plan Approved on an Interim Basis for Omega Therapeutics, Inc.	CI
09/06/25	First Motion for Exclusivity Period Extension Filed by Omega Therapeutics, Inc.	CI
27/05/25	Combined Liquidation Plan and Disclosure Statement Filed by Omega Therapeutics, Inc.	CI
25/04/25	Revised Stalking Horse APA	CI
23/04/25	Motion for Asset Sale Filed by Omega Therapeutics, Inc.	CI
04/04/25	Notice of Cancellation of auction	CI
12/03/25	Bidding Procedure Approved for Omega Therapeutics, Inc.	CI
12/03/25	Final DIP Financing Approved for Omega Therapeutics, Inc.	CI
23/02/25	Omega Therapeutics, Inc.(OTCPK:OMGA.Q) dropped from NASDAQ Composite Index	CI
23/02/25	Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from S&P TMI Index	CI

15/11/24	Raymond James Downgrades Omega Therapeutics to Market Perform From Outperform	MT
07/08/24	Chardan Adjusts Price Target on Omega Therapeutics to $7 From $6, Maintains Buy Rating	MT
18/06/24	Raymond James Initiates Omega Therapeutics at Outperform Rating With $12 Price Target	MT
03/04/24	Piper Sandler Trims Price Target on Omega Therapeutics to $9 From $10, Maintains Overweight Rating	MT
01/04/24	Chardan Cuts Price Target on Omega Therapeutics to $7 From $12, Keeps Buy Rating	MT

OMEA THER Share Price

Stocks

OMGA

US68217N1054

Investment Holding Companies

Valuation: OMEA THER

Latest news: OMEA THER

Analysts' recommendations: OMEA THER

Press Releases: OMEA THER

News in other languages: OMEA THER

Quotes and Performance

Price Extremes

Managers and Directors: OMEA THER

Latest insider transactions

Shell Companies

Financials

Company Profile

21/11/24	Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies	AQ
14/11/24	Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results	GL
15/10/24	Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings	AQ
15/10/24	Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings	GL
27/09/24	Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry	AQ

04/01/24	Novo Nordisk signe des partenariats de recherche avec des biotechs américaines
04/01/24	Novo Nordisk : accords de recherche avec Omega et Cellarity

Manager	Title	Age	Since
Kaan Certel CEO	Chief Executive Officer	56	13/11/2024
Barbara Chan DFI	Director of Finance/CFO	62	30/05/2024
Jennifer Nelson CTO	Chief Tech/Sci/R&D Officer	-	13/08/2024

Director	Title	Age	Since
Elliott Levy BRD	Director/Board Member	67	28/02/2021
Rainer Boehm BRD	Director/Board Member	65	31/08/2022
Kaan Certel BRD	Director/Board Member	56	13/11/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03/12/24	Ravi Mehrotra	Free	Director	50,000	0.0903%
22/11/24	Jennifer Nelson	Other	Chief Technology Officer	110,000	0.1994%
22/11/24	Jennifer Nelson	Free	Chief Technology Officer	110,000	0.1994%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OMEA THER	+50.00%	-.--%	-.--%	-99.87%	166K
CHURCHILL CAPITAL CORP XI	-3.06%	-11.27%	-	-	692M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	-0.10%	-	-	647M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.19%	+0.49%	-	-	602M
CHURCHILL CAPITAL CORP XII	+0.65%	+1.36%	-	-	599M
CANTOR EQUITY PARTNERS IV, INC.	0.00%	0.00%	+0.98%	-	589M
CENTIEL AG	0.00%	-6.29%	+279.62%	-72.91%	587M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.09%	-0.80%	+3.43%	-	552M
RICE ACQUISITION CORPORATION 3	-1.82%	+2.56%	-	-	506M
Average	+5.28%	-9.67%	+71.01%	-86.39%	530.52M
Weighted average by Cap.	-0.33%	-0.61%	+96.41%	-72.92%

	2022	2023
Net sales	2.07 1.82 1.72 1.56 2.94 198.99 2.95 20.64 7.97 101.54 7.78 7.61 326.3	3.09 2.72 2.57 2.33 4.38 297 4.41 30.81 11.9 151.55 11.62 11.36 487
Net income	-103M -90.33M -85.41M -77.47M -145M -9.86B -146M -1.02B -395M -5.03B -386M -377M -16.17B	-97.43M -85.69M -81.03M -73.49M -138M -9.35B -139M -970M -375M -4.77B -366M -358M -15.34B
Net Debt	-102M -89.8M -84.91M -77.02M -145M -9.8B -145M -1.02B -393M -5B -383M -375M -16.07B	55M 48.37M 45.74M 41.49M 77.92M 5.28B 78.37M 548M 212M 2.69B 206M 202M 8.66B

3 years	0		6.3
5 years	0		31.41
10 years	0		31.41